The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy
Open Access
- 15 February 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 2322
Abstract
Fibrosis is a chronic pathology resulting from excessive deposition of extracellular matrix components that leads to the loss of tissue function. Pulmonary fibrosis can follow a variety of diverse insults including ischemia, respiratory infection, or exposure to ionizing radiation. Consequently, treatments that attenuate the development of debilitating fibrosis are in desperate need across a range of conditions. Sphingolipid metabolism is a critical regulator of cell proliferation, apoptosis, autophagy, and pathologic inflammation, processes that are all involved in fibrosis. Opaganib (formerly ABC294640) is the first-in-class investigational drug targeting sphingolipid metabolism for the treatment of cancer and inflammatory diseases. Opaganib inhibits key enzymes in sphingolipid metabolism, including sphingosine kinase-2 and dihydroceramide desaturase, thereby reducing inflammation and promoting autophagy. Herein, we demonstrate in mouse models of lung damage following exposure to ionizing radiation that opaganib significantly improved long-term survival associated with reduced lung fibrosis, suppression of granulocyte infiltration, and reduced expression of IL-6 and TNFα at 180 days after radiation. These data further demonstrate that sphingolipid metabolism is a critical regulator of fibrogenesis, and specifically show that opaganib suppresses radiation-induced pulmonary inflammation and fibrosis. Because opaganib has demonstrated an excellent safety profile during clinical testing in other diseases (cancer and COVID-19), the present studies support additional clinical trials with this drug in patients at risk for pulmonary fibrosis.Keywords
Funding Information
- Biomedical Advanced Research and Development Authority (BARDA) (HHSO100201100029C, 261201400016C-0-0-1)
- US Department of Defense (HHSO100201100029C, 261201400016C-0-0-1)
- National Cancer Institute (HHSO100201100029C, 261201400016C-0-0-1)
This publication has 56 references indexed in Scilit:
- Inhibition of Sphingosine Kinase-2 in a Murine Model of Lupus NephritisPLOS ONE, 2013
- Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine KinasesPLOS ONE, 2012
- Inhibition of Sphingosine Kinase-2 Suppresses Inflammation and Attenuates Graft Injury after Liver Transplantation in RatsPLOS ONE, 2012
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2The Journal of Pharmacology and Experimental Therapeutics, 2010
- Transforming Growth Factor-β1 Induces Transdifferentiation of Myoblasts into Myofibroblasts via Up-Regulation of Sphingosine Kinase-1/S1P3 AxisMolecular Biology of the Cell, 2010
- Opposite Effects of Dihydrosphingosine 1-Phosphate and Sphingosine 1-Phosphate on Transforming Growth Factor-β/Smad Signaling Are Mediated through the PTEN/PPM1A-dependent PathwayJournal of Biological Chemistry, 2008
- Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine KinaseDigestive Diseases and Sciences, 2007
- Temporal Onset of Hypoxia and Oxidative Stress After Pulmonary IrradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Intestinal oxidative damage in inflammatory bowel disease: semi‐quantification, localization, and association with mucosal antioxidantsThe Journal of Pathology, 2003